# US 7,745,586 B2 · Human E3α ubiquitin ligase family

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,586 B2
- Document ID: US7745586B2
- Status: Granted
- Kind: B2
- Application number: 12/186,998
- Filed: 2008-08-06
- Published: 2009-04-16
- Granted: 2010-06-29
- Earliest claimed: 2000-03-08
- Assignees: Amgen Inc.
- Inventors: Hui-Quan Han; Keith Kwak
- Web page: https://patentgrep.com/patent/US7745586B2

## CPC

- C12N 9/93: {Ligases (6)}
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.

## Claims

### Claim 1

An isolated antibody or fragment thereof that specifically binds the polypeptide comprising the amino acid sequence selected from the group consisting of:
(a) the amino acid sequence set forth in SEQ ID NO: 2;
(b) an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 2, wherein the polypeptide has the E3α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2; and
(c) the amino acid sequence set forth in SEQ ID NO: 2 with 1 to about 100 conservative amino acid substitution(s), wherein the polypeptide has the E3α ubiquitin ligase activity of the polypeptide set forth in SEQ ID NO: 2.

### Claim 2 (depends on 1)

The antibody or fragment thereof of claim 1 that is a humanized antibody or fragment thereof.

### Claim 3 (depends on 1)

The antibody or fragment thereof of claim 1 that is a human antibody or fragment thereof.

### Claim 4 (depends on 1)

The antibody or fragment thereof of claim 1 that is a polyclonal antibody or fragment thereof.

### Claim 5 (depends on 1)

The antibody or fragment thereof of claim 1 that is a monoclonal antibody or fragment thereof.

### Claim 6 (depends on 1)

The antibody or fragment thereof of claim 1 that is a chimeric antibody or fragment thereof.

### Claim 7 (depends on 1)

The antibody or fragment thereof of claim 1 that is a CDR-grafted antibody or fragment thereof.

### Claim 8 (depends on 1)

The antibody or fragment thereof of claim 1 that is an antiidiotypic antibody or fragment thereof.

### Claim 9 (depends on 1)

The antibody or fragment thereof of claim 1 which is a variable region fragment.

### Claim 10 (depends on 9)

The variable region fragment of claim 9 which is a Fab or a Fab′ fragment.

### Claim 11 (depends on 1)

The antibody or fragment thereof of claim 1 which is bound to a detectable label.

### Claim 12 (depends on 1)

A method of detecting or quantitating the amount of huE3α ubiquitin ligase polypeptide in a sample using the anti-huE3α antibody or fragment thereof of claim 1, comprising:
(a) obtaining a sample;
(b) contacting the sample with an antibody or fragment thereof according to claim 1 under conditions which allow for the antibody to bind to the huE3α ubiquitin ligase polypeptide;
(c) detecting antibody binding to huE3α ubiquitin lipase polypeptide in the biological sample, wherein the detection of antibody binding is indicative of the presence of huE3α ubiquitin ligase polypeptide in said sample; and
(d) comparing the level of antibody binding to huE3α ubiquitin polypeptide within said sample and the level of the antibody binding to a known concentration of huE3α ubiquitin ligase polypeptide.

### Claim 13 (depends on 1)

A method for determining the presence and/or concentration of huE3α ubiquitin ligase polypeptide in a biological sample comprising the steps of:
(a) obtaining a biological sample;
(b) contacting the biological sample with an antibody according to claim 1 under conditions which allow for the antibody to bind to the huE3α ubiquitin ligase polypeptide;
(c) detecting antibody binding to huE3α ubiquitin ligase polypeptide in the biological sample, wherein the detection of antibody binding is indicative of the presence of huE3α ubiquitin ligase polypeptide in said biological sample; and
(d) comparing the level of antibody binding to huE3α ubiquitin ligase polypeptide within said biological sample and the level of the antibody binding to a known concentration of huE3α ubiquitin ligase polypeptide.